{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:36:13Z","timestamp":1791246973960,"version":"4.1.0"},"reference-count":39,"publisher":"American Society of Hematology","issue":"22","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,28]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Briquilimab is a monoclonal antibody inhibiting stem cell factor (SCF) binding to CD117 (c-Kit). Based on preclinical data demonstrating the antibody clears hematopoietic stem and progenitor cells (HSPC) and myeloid malignant cells, we conducted a phase 1 trial examining briquilimab plus nonmyeloablative fludarabine (Flu) and total body irradiation (TBI) as conditioning for older adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) undergoing matched donor allogeneic hematopoietic cell transplantation (HCT). Briquilimab was infused 10 to 14 days before transplant day (TD) 0; Flu 30 mg\/m2 and TBI 2 to 3 Gy were administered on TD \u22124 to \u22122 and TD0, respectively. Graft-versus-host disease prophylaxis consisted of tacrolimus, sirolimus, and mycophenolate mofetil. Thirty-two patients enrolled (n = 13 AML in complete remission [CR]; n = 3 AML in relapse; n = 16 MDS). Median age was 70 years, and most had detectable measurable residual disease (MRD) at screening. There were no briquilimab infusion reactions, dose-limiting toxicities, or primary graft failure events; briquilimab clearance was predictable across patients. Among the AML in CR cohort, 1-year event-free survival (EFS) was 69.2%; 1-year overall survival (OS) was 75%. Among the MDS cohort, 1-year EFS was 53.8%; 1-year OS was 76.4%. One of 3 patients with AML in relapse experienced a transient response. Marrow samples obtained before and after briquilimab and before Flu\/TBI demonstrated AML\/MDS HSPC depletion (mean, 62.4% \u00b1 22.7%) with resultant threefold increase in serum SCF. In summary, we demonstrate the feasibility, safety, and proof of concept of CD117 targeting with briquilimab as HCT conditioning for AML\/MDS. The trial was registered at www.clinicaltrials.gov as NCT04429191.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025031858","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T19:03:08Z","timestamp":1772737388000},"page":"2610-2620","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":8,"title":["Nonmyeloablative conditioning combined with the anti-CD117 antibody briquilimab in older adults with high-risk AML and MDS"],"prefix":"10.1182","volume":"147","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9887-6136","authenticated-orcid":false,"given":"Lori","family":"Muffly","sequence":"first","affiliation":[{"name":"1Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine J.","family":"Lee","sequence":"additional","affiliation":[{"name":"2Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA"},{"name":"3Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arpita","family":"Gandhi","sequence":"additional","affiliation":[{"name":"4Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4524-9451","authenticated-orcid":false,"given":"Ankur","family":"Varma","sequence":"additional","affiliation":[{"name":"5Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9620-7839","authenticated-orcid":false,"given":"Bart L.","family":"Scott","sequence":"additional","affiliation":[{"name":"2Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9949-3615","authenticated-orcid":false,"given":"Sagar S.","family":"Patel","sequence":"additional","affiliation":[{"name":"3Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6721-0358","authenticated-orcid":false,"given":"Parveen","family":"Shiraz","sequence":"additional","affiliation":[{"name":"1Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minyoung","family":"Youn","sequence":"additional","affiliation":[{"name":"6Jasper Therapeutics, Inc, Redwood City, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikako","family":"Yanagiba","sequence":"additional","affiliation":[{"name":"6Jasper Therapeutics, Inc, Redwood City, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeyakavitha","family":"Arulprakasam","sequence":"additional","affiliation":[{"name":"6Jasper Therapeutics, Inc, Redwood City, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Le","sequence":"additional","affiliation":[{"name":"6Jasper Therapeutics, Inc, Redwood City, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye-sook","family":"Kwon","sequence":"additional","affiliation":[{"name":"6Jasper Therapeutics, Inc, Redwood City, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janel","family":"Long-Boyle","sequence":"additional","affiliation":[{"name":"7Division of Pediatric Allergy, Immunology, and Bone Marrow Transplantation, Department of Pediatrics, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith A.","family":"Shizuru","sequence":"additional","affiliation":[{"name":"1Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University, Stanford, CA"},{"name":"6Jasper Therapeutics, Inc, Redwood City, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3707-2767","authenticated-orcid":false,"given":"Wendy W.","family":"Pang","sequence":"additional","affiliation":[{"name":"6Jasper Therapeutics, Inc, Redwood City, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0803-9607","authenticated-orcid":false,"given":"Andrew S.","family":"Artz","sequence":"additional","affiliation":[{"name":"8Department of Hematology & Hematopoietic Cell Transplant, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"9","key":"2026052811220047100_bib1","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1182\/blood-2017-03-772368","article-title":"Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States","volume":"130","author":"Muffly","year":"2017","journal-title":"Blood"},{"issue":"12","key":"2026052811220047100_bib2","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"2026052811220047100_bib3","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.2016.70.7091","article-title":"Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes","volume":"35","author":"Scott","year":"2017","journal-title":"J Clin Oncol"},{"issue":"9","key":"2026052811220047100_bib4","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1001\/jama.2023.1363","article-title":"DNA sequencing to detect residual disease in adults with acute myeloid leukemia prior to hematopoietic cell transplant","volume":"329","author":"Dillon","year":"2023","journal-title":"JAMA"},{"issue":"12","key":"2026052811220047100_bib5","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.exphem.2003.08.015","article-title":"Membrane-bound stem cell factor is a key regulator in the initial lodgment of stem cells within the endosteal marrow region","volume":"31","author":"Driessen","year":"2003","journal-title":"Exp Hematol"},{"issue":"5854","key":"2026052811220047100_bib6","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1126\/science.1149726","article-title":"Efficient transplantation via antibody-based clearance of hematopoietic stem cell niches","volume":"318","author":"Czechowicz","year":"2007","journal-title":"Science"},{"issue":"19","key":"2026052811220047100_bib7","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1182\/blood-2018-06-853879","article-title":"Anti-human CD117 antibody-mediated bone marrow niche clearance in nonhuman primates and humanized NSG mice","volume":"133","author":"Kwon","year":"2019","journal-title":"Blood"},{"issue":"19","key":"2026052811220047100_bib8","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1182\/blood-2018-06-858159","article-title":"Anti-CD117 antibody depletes normal and myelodysplastic syndrome human hematopoietic stem cells in xenografted mice","volume":"133","author":"Pang","year":"2019","journal-title":"Blood"},{"issue":"24","key":"2026052811220047100_bib9","doi-asserted-by":"crossref","first-page":"5419","DOI":"10.1182\/blood-2010-07-295949","article-title":"Antibody targeting KIT as pretransplantation conditioning in immunocompetent mice","volume":"116","author":"Xue","year":"2010","journal-title":"Blood"},{"issue":"suppl 1","key":"2026052811220047100_bib10","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1182\/blood-2019-126239","article-title":"Non-genotoxic anti-CD117 antibody conditioning results in successful hematopoietic stem cell engraftment in patients with severe combined immunodeficiency [abstract]","volume":"134","author":"Agarwal","year":"2019","journal-title":"Blood"},{"issue":"9","key":"2026052811220047100_bib11","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1038\/s41591-025-03817-1","article-title":"Irradiation- and busulfan-free stem cell transplantation in Fanconi anemia using an anti-CD117 antibody: a phase 1b trial","volume":"31","author":"Agarwal","year":"2025","journal-title":"Nat Med"},{"issue":"suppl 1","key":"2026052811220047100_bib12","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1182\/blood-2024-200214","article-title":"Adding CD117 antibody to alemtuzumab, low dose total body irradiation (TBI), and sirolimus for matched related donor (MRD) hematopoietic cell transplant (HCT) in sickle cell disease (SCD): initial results","volume":"144","author":"Hsieh","year":"2024","journal-title":"Blood"},{"issue":"6","key":"2026052811220047100_bib13","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.3324\/haematol.2018.199398","article-title":"Total body irradiation dose escalation decreases risk of progression and graft rejection after hematopoietic cell transplantation for myelodysplastic syndromes or myeloproliferative neoplasms","volume":"104","author":"Monaco","year":"2019","journal-title":"Haematologica"},{"issue":"suppl 1","key":"2026052811220047100_bib14","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1182\/blood-2020-137762","article-title":"First report of non-genotoxic conditioning with JSP191 (anti-CD117) and hematopoietic stem cell transplantation in a newly diagnosed patient with severe combined immune deficiency","volume":"136","author":"Agarwal","year":"2020","journal-title":"Blood"},{"issue":"8","key":"2026052811220047100_bib15","doi-asserted-by":"crossref","first-page":"e409","DOI":"10.1016\/S2352-3026(19)30088-2","article-title":"Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial","volume":"6","author":"Sandmaier","year":"2019","journal-title":"Lancet Haematol"},{"issue":"25","key":"2026052811220047100_bib16","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bola\u00f1os-Meade","year":"2023","journal-title":"N Engl J Med"},{"key":"2026052811220047100_bib17","unstructured":"National Cancer Institute\n          . Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. US Department of Health and Human Services. 2017. Accessed 17 June 2025. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm."},{"issue":"1","key":"2026052811220047100_bib18","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","article-title":"International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium","volume":"22","author":"Harris","year":"2016","journal-title":"Biol Blood Marrow Transpl"},{"issue":"3","key":"2026052811220047100_bib19","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"2026052811220047100_bib20","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Dohner","year":"2022","journal-title":"Blood"},{"issue":"3-4","key":"2026052811220047100_bib21","first-page":"257","article-title":"Stem cell factor as a survival and growth factor in human normal and malignant hematopoiesis","volume":"95","author":"Hassan","year":"1996","journal-title":"Acta Haematol"},{"issue":"2","key":"2026052811220047100_bib22","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1182\/blood.V81.2.324.324","article-title":"Inhibition of c-kit ligand\/steel factor by antibodies reduces survival of lethally irradiated mice","volume":"81","author":"Neta","year":"1993","journal-title":"Blood"},{"issue":"9","key":"2026052811220047100_bib23","first-page":"923.e1","article-title":"Pharmacokinetics of briquilimab as a conditioning agent for hematopoietic stem cell transplantation in patients with severe combined immunodeficiency, myelodysplastic syndrome, or acute myeloid leukemia","volume":"30","author":"Jung","year":"2024","journal-title":"Transpl Cell Ther"},{"issue":"2","key":"2026052811220047100_bib24","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/S2666-6367(23)00155-0","article-title":"Evaluation of clinical outcomes and healthcare resource use of outpatient allogeneic stem cell transplant in older adults with AML\/MDS, using JSP191, an anti-CD117 monoclonal antibody, in combination with low dose irradiation and fludarabine conditioning: a single center analysis","volume":"29","author":"Muffly","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"15","key":"2026052811220047100_bib25","doi-asserted-by":"crossref","first-page":"4570","DOI":"10.1182\/bloodadvances.2022007168","article-title":"Impact of MRD status in patients with AML undergoing allogeneic stem cell transplantation in the first vs the second remission","volume":"6","author":"Jentzsch","year":"2022","journal-title":"Blood Adv"},{"issue":"12","key":"2026052811220047100_bib26","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1200\/JCO.19.03011","article-title":"Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease","volume":"38","author":"Hourigan","year":"2020","journal-title":"J Clin Oncol"},{"issue":"7","key":"2026052811220047100_bib27","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.bbmt.2016.03.029","article-title":"Minimal identifiable disease and the role of conditioning intensity in hematopoietic cell transplantation for myelodysplastic syndrome and acute myelogenous leukemia evolving from myelodysplastic syndrome","volume":"22","author":"Festuccia","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"2026052811220047100_bib28","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1200\/JCO.2012.45.0247","article-title":"Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation","volume":"31","author":"Storb","year":"2013","journal-title":"J Clin Oncol"},{"issue":"7","key":"2026052811220047100_bib29","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1182\/blood.V78.7.1706.1706","article-title":"Enrichment and characterization of murine hematopoietic stem cells that express c-kit molecule","volume":"78","author":"Okada","year":"1991","journal-title":"Blood"},{"issue":"14","key":"2026052811220047100_bib30","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1158\/1078-0432.CCR-17-3786","article-title":"Mechanistic insights of an immunological adverse event induced by an anti-KIT antibody drug conjugate and mitigation strategies","volume":"24","author":"L'Italien","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"5-6","key":"2026052811220047100_bib31","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1089\/hum.2023.29236.bfs","article-title":"Magenta halts development, pursues strategic alternatives after patient death","volume":"34","author":"Philippidis","year":"2023","journal-title":"Hum Gene Ther"},{"issue":"10","key":"2026052811220047100_bib32","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1038\/s41375-020-0818-9","article-title":"Anti-human CD117 CAR T-cells efficiently eliminate healthy and malignant CD117-expressing hematopoietic cells","volume":"34","author":"Myburgh","year":"2020","journal-title":"Leukemia"},{"key":"2026052811220047100_bib33","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.omto.2023.07.003","article-title":"Anti-CD117 CAR T cells incorporating a safety switch eradicate human acute myeloid leukemia and hematopoietic stem cells","volume":"30","author":"Magnani","year":"2023","journal-title":"Mol Ther Oncolytics"},{"issue":"9","key":"2026052811220047100_bib34","doi-asserted-by":"crossref","first-page":"4584","DOI":"10.1016\/j.ymthe.2025.05.033","article-title":"Targeting CD117 on hematopoietic stem and progenitor cells impairs CAR T cell activity","volume":"33","author":"Thomas","year":"2025","journal-title":"Mol Ther"},{"key":"2026052811220047100_bib35","doi-asserted-by":"crossref","first-page":"1294555","DOI":"10.3389\/fimmu.2023.1294555","article-title":"Ligand-based targeting of c-kit using engineered \u03b3\u03b4 T cells as a strategy for treating acute myeloid leukemia","volume":"14","author":"Branella","year":"2023","journal-title":"Front Immunol"},{"issue":"11","key":"2026052811220047100_bib36","doi-asserted-by":"crossref","first-page":"e70055","DOI":"10.1002\/hem3.70055","article-title":"A single-chain variable fragment-based bispecific T-cell activating antibody against CD117 enables T-cell mediated lysis of acute myeloid leukemia and hematopoietic stem and progenitor cells","volume":"8","author":"Volta","year":"2024","journal-title":"Hemasphere"},{"issue":"12","key":"2026052811220047100_bib37","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1021\/acsmedchemlett.9b00468","article-title":"Discovery of potent and selective antibody-drug conjugates with Eg5 inhibitors through linker and payload optimization","volume":"10","author":"Karpov","year":"2019","journal-title":"ACS Med Chem Lett"},{"issue":"1","key":"2026052811220047100_bib38","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1158\/1535-7163.MCT-25-0396","article-title":"Preclinical antitumor efficacy of a novel anti-c-Kit antibody-drug conjugate, NN3201, in c-Kit-positive tumors","volume":"25","author":"Kim","year":"2025","journal-title":"Mol Cancer Ther"},{"issue":"22","key":"2026052811220047100_bib39","doi-asserted-by":"crossref","first-page":"2425394","DOI":"10.1002\/adfm.202425394","article-title":"Engineering novel DNA nanoarchitectures for targeted drug delivery and aptamer mediated apoptosis in cancer therapeutics","volume":"35","author":"Dwivedy","year":"2025","journal-title":"Adv Funct Mater"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/22\/2610\/2522828\/blood_bld-2025-031858-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/22\/2610\/2522828\/blood_bld-2025-031858-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T15:22:11Z","timestamp":1779981731000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/147\/22\/2610\/566932\/Nonmyeloablative-conditioning-combined-with-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":39,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2026,5,28]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025031858","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5,28]]},"published":{"date-parts":[[2026,5,28]]}}}